AOAyse Ozer

Ayse Ozer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayse Ozer has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of Certain Biochemical Parameters Related to Bone Cycle with Genotype in MPS III-B Patients

    by Seda Gökkurt, İrEm Peker Eyüboğlu, Banu Nur Güzel, Ercan Mihçi, Ayşe Özer, Mustafa Akki̇pRi̇k

    Background/aim: The aim of this study is to investigate the genotype-phenotype correlation in Sanfilippo type B patients in terms of bone formation/resorption parameters, and to determine the release/inhibition of biomarkers accompanying osteoporosis.Materials and Methods: Plasma levels of Osteoprotegerin, Matrix metalloproteinases (MMP2, MMP9), TIMP-1, TIMP-2, BALP, Cathepsin K, and TRACP-5b were examined by ELISA method in MPS IIIB patients. At the same time, mutations in the NAGLU gene causing this disease were detected by whole exome sequencing, and their correlation with biochemical parameters was investigated.Results: Based on the enzyme analysis results, MMP-9, TIMP1, TIMP-2, and MMP-2 were significantly high, while Cathepsin-K was low in the the study group. Osteoprotegerin levels were similar between the two groups, while Cathepsin K levels were higher in the control group. In this study, genetic analysis of patients with MPS-IIIB disease was performed. The analysis was performed by sequencing all exons and exon-intron junction regions of the NAGLU gene using a next generation sequencing system. In this way, variations were detected qualitatively with high read depths. As a result of the analyses, only 2 patients had a previously pathogenically defined alteration. In addition, as a result of the impact-assessment analyses, alterations that have a modifying effect on protein structure were also detected.Conclusion: Regarding to genetic analysis results, it is necessary to consider the change classified as benign in the OMIM database as pathogenic because the changes (p.Arg737Gly and p.Trp103Cys) found in patients have somehow altered enzyme activity. A novel NAGLU gene mutation, p. Trp103Cys was detected in one patient. The p.Trp103Cys mutation in the first exon was shown the first time, additionally, SIFT and PolyPhen analyses confirmed this variation as "damaging." Therefore, future functional analyses of the variation can be conducted to carry out a more comprehensive study.

  • Correlation between the DNA methylation and gene expression of IGFBP5 in breast cancer

    by Sevgi Karabulut, Zehra Kaya, Gökçe Gūllū Amuran, Irem Peker, Tolga Özmen, Bahadır M. Gūllūoḡlu, Handan Kaya, Can Erzik, Ayşe Ōzer, Mustafa Akkiprik

    BACKGROUND: The insulin-like growth factor binding protein5 (IGFBP5) is often dysregulated in human cancers and considered neither a tumor suppressor nor an oncogene. OBJECTIVE: We aim to examine the reason of the changeable gene regulation of IGFBP5


  • Comparison of telomere length and insulin-like growth factor-binding protein 7 promoter methylation between breast cancer tissues and adjacent normal tissues in Turkish women

    by Zehra Kaya, Mustafa Akkiprik, Sevgi Karabulut, Irem Peker, Gokce Gullu Amuran, Tolga Ozmen, Bahadır M. Gulluoglu, Handan Kaya, Ayse Ozer

    Both insulin-like growth factor-binding protein 7 (IGFBP7) and telomere length (TL) are associated with proliferation and senescence of human breast cancer. This study assessed the clinical significance of both TL and IGFBP7 methylation status in breast cancer tissues compared with adjacent normal tissues. We also investigated whether IGFBP7 methylation status could be affecting TL. Telomere length was measured by quantitative PCR to compare tumors with their adjacent normal tissues. The IGFBP7 promoter methylation status was evaluated by methylation-specific PCR and its expression levels were determined by western blotting. Telomeres were shorter in tumor tissues compared to controls (P<.0001). The mean TL was higher in breast cancer with invasive ductal carcinoma (IDC; n=72; P=.014) compared with other histological type (n=29), and TL in IDC with HER2 negative (n=53; P=.017) was higher than TL in IDC with HER2 positive (n=19). However, telomeres were shortened in advanced stages and growing tumors. IGFBP7 methylation was observed in 90% of tumor tissues and 59% of controls (P=.0002). Its frequency was significantly higher in IDC compared with invasive mixed carcinoma (IMC; P=.002) and it was not correlated either with protein expression or the other clinicopathological parameters. These results suggest that IGFBP7 promoter methylation and shorter TL in tumor compared with adjacent tissues may be predictive biomarkers for breast cancer. Telomere maintenance may be indicative of IDC and IDC with HER2 (−) of breast cancer. Further studies with larger number of cases are necessary to verify this association.


  • Impact of glucocorticoid receptor gene (NR3C1) polymorphisms in Turkish patients with metabolic syndrome

    by Z. Kaya, S. Caglayan, M. Akkiprik, C. Aral, G. Ozisik, M. Ozata, A. Ozer

    Background The metabolic syndrome (MetS) is characterized by a cluster of metabolic factors, including insulin resistance and type-2 diabetes, abdominal obesity, dyslipidemia, hypertension and microalbuminuria. Impaired glucocorticoid receptor (GR) activity also plays an important role in the etiology of MetS. The objective of our study is to evaluate the effects of GR gene polymorphisms (BclI, N363S, TthIII1 and ER22/23EK) in Turkish patients with MetS. Materials and methods Seventy subjects with MetS and 185 healthy controls were enrolled in the study. PCR–RFLP analysis was used for genotyping. Results for each polymorphism have been verified by allele-specific oligonucleotide analysis. Results BclI GG genotype was significantly associated with an increased risk of MetS (p = 0.02). Also, only in women, the G allele carriers were significantly associated with higher C-peptide. T allele carriers of TthIII1 polymorphism were significantly associated with higher C-peptide, triglyceride, insulin and C-reactive protein (CRP, p value 0.048, 0.022, 0.005 and 0.022, respectively), and lower fasting blood glucose (FBG, p = 0.02). The combined carriers of BclI polymorphism G allele and TthIII1 polymorphism T allele were significantly associated with higher diastolic blood pressure in all patients, and lower FBG and postprandial blood glucose in only men. All the ER22/23EK polymorphisms coexisted with polymorphic variant of TthIII1 (p = 0.0058). Conclusion The presence of homozygote polymorphic variant of BclI might be good predictive markers for the disease susceptibility. The BclI and the TthIII1 polymorphism are associated with sex-specific clinical parameters. Our findings also suggest that the combination of BclI and TthIII1 polymorphisms may play a protective role in blood glucose.


  • Open Access

    Identification of Differentially Expressed IGFBP5-Related Genes in Breast Cancer Tumor Tissues Using cDNA Microarray Experiments

    by Mustafa Akkiprik, İrem Peker, Tolga Özmen, Gökçe Güllü Amuran, Bahadır M. Güllüoğlu, Handan Kaya, Ayşe Özer

    IGFBP5 is an important regulatory protein in breast cancer progression. We tried to identify differentially expressed genes (DEGs) between breast tumor tissues with IGFBP5 overexpression and their adjacent normal tissues. In this study, thirty-eight breast cancer and adjacent normal breast tissue samples were used to determine IGFBP5 expression by qPCR. cDNA microarrays were applied to the highest IGFBP5 overexpressed tumor samples compared to their adjacent normal breast tissue. Microarray analysis revealed that a total of 186 genes were differentially expressed in breast cancer compared with normal breast tissues. Of the 186 genes, 169 genes were downregulated and 17 genes were upregulated in the tumor samples. KEGG pathway analyses showed that protein digestion and absorption, focal adhesion, salivary secretion, drug metabolism-cytochrome P450, and phenylalanine metabolism pathways are involved. Among these DEGs, the prominent top two genes (MMP11 and COL1A1) which potentially correlated with IGFBP5 were selected for validation using real time RT-qPCR. Only COL1A1 expression showed a consistent upregulation with IGFBP5 expression and COL1A1 and MMP11 were significantly positively correlated. We concluded that the discovery of coordinately expressed genes related with IGFBP5 might contribute to understanding of the molecular mechanism of the function of IGFBP5 in breast cancer. Further functional studies on DEGs and association with IGFBP5 may identify novel biomarkers for clinical applications in breast cancer.


  • Open Access

    Detection of PIK3CA Gene Mutations with HRM Analysis and Association with IGFBP-5 Expression Levels in Breast Cancer

    by Ebubekir Dirican, Zehra Kaya, Gokce Gullu, Irem Peker, Tolga Ozmen, Bahadir M. Gulluoglu, Handan Kaya, Ayse Ozer, Mustafa Akkiprik

    Detection of PIK3CA Gene Mutations with HRM Analysis and Association with IGFBP-5 Expression Levels in Breast Cancer PIK3CA;PI3K;IGFBP5;HRM assay;Turkish breast cancer;mutation; Breast cancer is the second most common cancer and second leading cause of cancer deaths in women. Phosphatidylinositol-3-kinase (PI3K)/AKT pathway mutations are associated with cancer and phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene mutations have been observed in 25-45% of breast cancer samples. Insulin growth factor binding protein-5 (IGFBP-5) can show different effects on apoptosis, cell motility and survival in breast cancer. We here aimed to determine the association between PIK3CA gene mutations and IGFBP-5 expressions for the first time in breast cancer patients. Frozen tumor samples from 101 Turkish breast cancer patients were analyzed with high resolution melting (HRM) for PIK3CA mutations (exon 9 and exon 20) and 37 HRM positive tumor samples were analyzed by DNA sequencing, mutations being found in 31. PIK3CA exon 9 mutations (Q546R, E542Q, E545K, E542K and E545D) were found in 10 tumor samples, exon 20 mutations (H1047L, H1047R, T1025T and G1049R) in 21, where only 1 tumor sample had two exon 20 mutations (T1025T and H1047R). Moreover, we detected one sample with both exon 9 (E542Q) and exon 20 (H1047R) mutations. 35% of the tumor samples with high IGFBP-5 mRNA expression and 29.4% of the tumor samples with low IGFBP-5 mRNA expression had PIK3CA mutations (p=0.9924). This is the first study of PIK3CA mutation screening results in Turkish breast cancer population using HRM analysis. This approach appears to be a very effective and reliable screening method for the PIK3CA exon 9 and 20 mutation detection. Further analysis with a greater number of samples is needed to clarify association between PIK3CA gene mutations and IGFBP-5 mRNA expression, and also clinical outcome in breast cancer patients.


  • Open Access

    Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer

    by Mustafa Akkiprik, Yumei Feng, Huamin Wang, Kexin Chen, Limei Hu, Aysegul Sahin, Savitri Krishnamurthy, Ayse Ozer, Xishan Hao, Wei Zhang

    The insulin-like growth factor axis, which has been shown to protect cells from apoptosis, plays an essential role in normal cell physiology and in cancer development. The family of insulin-like growth factor binding proteins (IGFBPs) has been shown to have a diverse spectrum of functions in cell growth, death, motility, and tissue remodeling. Among the six IGFBP family members, IGFBP-5 has recently been shown to play an important role in the biology of breast cancer, especially in breast cancer metastasis; however, the exact mechanisms of action remain obscure and sometimes paradoxical. An in-depth understanding of IGFBP-5 would shed light on its potential role as a target for breast cancer therapeutics.


    • 1 March 2008
      • Vol. 19  (1) , 22-7

    Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients.

    by Mustafa Akkiprik, Ciğdem Ataizi Celikel, Fikret Düşünceli, Ozgür Sönmez, Bahadir M GÜLLÜOĞLU, Aydin Sav, Ayşe Ozer

    The activation of ras family genes plays an important role in colorectal tumorigenesis. We investigated the clinicopathological characteristics and point mutations of K-ras oncogene codons 12/13 and ras p21 expression using paraffinembedded materials from cancerous and the surrounding normal tissues of 53 colorectal cancer cases. K-ras codons 12 and 13 point mutations were analyzed by PCR-Single- Strand Conformational Polymorphism (SSCP) and followed by DNA sequencing, while ras p21 expression was evaluated using immunohistochemistry. Mutations of K-ras and overexpression of the ras p21 were detected in 11% and 76% of the tumors, respectively. Ras protein level in tumor was increased an average of 4.6-fold over that of normal mucosa. Ras p21 overexpression did not correlate with any of the clinicopathological parameters examined. K-ras gene mutations were found mostly in the presence of a mucinous component within the tumor (p=0.06). Follow-up data were available for 43 patients. There was no statistically significant correlation between these alterations and patient outcomes. Our data suggest that, apart from K-ras codons 12/13 point mutations, overexpression of the ras family genes is important in the development of the disease but it appears not to be predictive of survival. Furthermore, mucinous secretion in the colorectum may represent a distinct genetic pattern.


    • 1 March 2007
      • Vol. 16  (1) , 11-7

    Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.

    by Mustafa Akkiprik, Cigdem Ataizi-Celikel, Ciddem Ataizi-Celikel, Fikret Düşünceli, Ozgür Sönmez, Bahadir M Gulluoglu, Bahadýr M Güllüoglu, Aydin Sav, Aydýn Sav, Ayşe Ozer

    Genetic alterations of p53, K-ras and DCC genes have a pivotal role in the colorectal cancer progression. The aim of this study was to clarify the association between K-ras mutations, p53 aberrations and DCC loss of heterozygosity (LOH), with the patient outcome and tumor characteristics in 43 stage I-II colorectal cancer patients. Mutations in exons 5-8 of the p53 gene and codon 12 and/or 13 of the K-ras gene were assayed by PCR-SSCP and then confirmed by DNA sequencing. DCC LOH was studied by PCR-RFLP, while p53 immunohistochemistry was also made. Mutations of the p53 gene were found in 14 (32.5%) tumors. Five (12%) cases showed mutation of the K-ras gene. Nuclear staining of p53 was found in 22 (51 %) cases. DCC LOH was found in 5 (12%) cases. Cases with guanine to thymine substitution that occurred in K-ras codon 12 and DCC LOH were found to be more aggressive than other cases with codon 12 mutations or DCC wild-type phenotype. Many tumors with p53 over-expression were localized on the left side of the colon (p=0.005). The stage of the tumor was higher in patients who died during the follow-up period, when compared to the ones who have survived. Although none of these genetic alterations showed a significant prognostic value, specific mutation of K-ras gene and DCC LOH phenotype might have a predictive prognostic implication in colorectal cancer. Furthermore, different etiopathogenetic mechanisms might be involved in the tumorigenesis of the left and right colon.


  • Effect of BCG vaccination on cytokine mRNA expression in atopic children with asthma

    by Ayse Özer, Faruk Tükenmez, Anil Biricik, Isil B Barlan, Beyazit Çirakoglu, Müjdat M Başaran